Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna is leveraging over a decade of extensive research to advance a pipeline of differentiated small molecules engineered to stabilize CFTR’s nucleotide-binding domain 1 (NBD1), where the most common cystic fibrosis genetic mutation F508del resides. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR activity, which Sionna believes is central to unlocking dramatic improvements in clinical outcomes and quality of life for cystic fibrosis patients.
MassBio Member Spotlight: Sionna Therapeutics
Location: Waltham, MA
Website: sionnatx.com
Leadership:
- Mike Cloonan, President and Chief Executive Officer
- Charlotte McKee, M.D., Chief Medical Officer
- Elena Ridloff, C.F.A., Chief Financial Officer & Head of Corporate Development
- Vanya Sagar, Chief People OfficerGreg Hurlbut, Ph.D., Co-Founder and Senior Vice President, Discovery Research
- Mark Munson, Ph.D., Co-Founder and Senior Vice President, Medicinal Chemistry
Therapeutic Area(s): Cystic Fibrosis